Clinical Trials Directory

Trials / Terminated

TerminatedNCT02743793

A Cohort Study of Operationally Tolerant Allograft Recipients

A Prospective Cohort Study of Operationally Tolerant Allograft Recipients (ITN063ST)

Status
Terminated
Phase
Study type
Observational
Enrollment
41 (actual)
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID) · NIH
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Antirejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent their bodies from rejecting the new organ. Some organ transplant recipients can stop taking anti-rejection medicines without rejecting their transplanted organ (this is called 'tolerance'). The purpose of this study will collect samples and data from 'tolerant' liver or kidney transplant recipients in order to find out: The purpose of this study is to collect samples and data in order to find out: * How long liver or kidney transplant recipients can remain tolerant; * What happens in the tolerant recipient's body over time; and * If there are patterns in the body that are linked to tolerance.

Detailed description

This is a multi-center, prospective, observational study in which operationally tolerant recipients of liver or kidney allografts will be followed longitudinally, with annual collections of clinical data and biological samples. All participants will be followed for the duration of the study, regardless of changes in their tolerance status. Participants will be recruited by three main pathways: 1. Tolerant participants from current and past Immune Tolerance Network (ITN) trials, including those who have already completed trial participation and those who are anticipated to complete trial participation, 2. Tolerant participants referred by ITN affiliated investigators, academic and community transplant physicians and directly through outreach to transplant affinity groups such as the National Kidney Foundation (NKF), and 3. Tolerant participants from the general transplant community who are reachable through general contact channels such as the ITN website, word-of-mouth referrals from existing participants, and social media.

Conditions

Interventions

TypeNameDescription
PROCEDUREBlood Draw

Timeline

Start date
2016-06-30
Primary completion
2020-03-24
Completion
2020-03-24
First posted
2016-04-19
Last updated
2021-09-21
Results posted
2021-09-21

Locations

5 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02743793. Inclusion in this directory is not an endorsement.